样式: 排序: IF: - GO 导出 标记为已读
-
Vasoplegic Syndrome during Heart Transplantation: A Systematic Review and Meta-analysis J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-28 Nicolas Kumar, Michael G. Fitzsimons, Manoj H. Iyer, Michael Essandoh, Julia E. Kumar, Adam A. Dalia, Asishana Osho, Tamara R. Sawyer, Amit Bardia
Vasoplegic syndrome (VS) is a common occurrence during heart transplantation (HT). It currently lacks a uniform definition between transplant centers, and its pathophysiology and treatment remain enigmatic. This systematic review summarizes the available published clinical data regarding VS during HT. We searched databases for all published reports on VS during HT. Data collected included the incidence
-
Randomized Trial Of Routine Versus On-demand Intraoperative Extracorporeal Membrane Oxygenation In Lung Transplantation: A Feasibility Study J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-28 Basil Nasir, Jason Weatherald, Tim Ramsay, Marcelo Cypel, Laura Donahoe, Chris Durkin, Travis Schisler, Jayan Nagendran, Moishe Liberman, Caroline Landry, Charles Overbeek, Alex Moore, Pasquale Ferraro
In most centers, extracorporeal membrane oxygenation (ECMO) is the preferred means to provide cardiopulmonary support during lung transplantation. However, there is controversy about whether intraoperative venoarterial (VA) ECMO should be used routinely or selectively. A randomized controlled trial is the best way to address this controversy. In this publication, we describe a feasibility study to
-
Post-transplant Survival after Normothermic Regional Perfusion vs Direct Procurement and Perfusion in Donation after Circulatory Determination of Death Heart Transplantation J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-27 Gege Ran, Anji E. Wall, Nikhil Narang, Kiran K. Khush, Jordan R.H. Hoffman, Kevin C Zhang, William F. Parker
Since 2019, the annual transplantation rate of hearts donated following circulatory death (DCD) has increased significantly in the United States. The two major heart procurement techniques following circulatory death are direct procurement and perfusion (DPP) and normothermic regional perfusion (NRP). Post-transplant survival for heart recipients has not been compared between these two techniques.
-
Impact of a Positive Crossmatch on Pediatric Heart Transplant Outcomes J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-27 Caitlin Milligan, Ryan J. Williams, Tajinder P. Singh, Heather J. Bastardi, Paul Esteso, Christopher S.D. Almond, Kimberlee Gauvreau, Kevin P. Daly
Pediatric heart transplant (HT) candidates experience high waitlist mortality due to a limited donor pool that is constrained in part by anti-HLA sensitization. We evaluated the impact of CDC and Flow donor-specific crossmatch (XM) results on pediatric HT outcomes. All pediatric HT between 1999 and 2019 in the OPTN database were included. Donor-specific XM results were sub-categorized based on CDC
-
COVID-19 infection is mild and has minimal impact on lung function in well vaccinated and widely treated lung transplant recipients J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-24 Samantha L. Ennis, Bronwyn J. Levvey, Helen V. Shingles, Sue J. Lee, Gregory I. Snell, Bradley J. Gardiner
COVID-19 has become a common infection affecting lung transplant recipients (LTR), who are at high risk for poor outcomes. Outcomes early in the pandemic were poor, but since the rollout of vaccination and novel COVID-19 treatments, outcomes of LTR have not been well described. Our aim was to evaluate the effect of COVID-19 on the clinical course and lung function trajectory in an Australian cohort
-
Influence of socioeconomic status on rates of advanced heart failure therapies J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-24 Johan E. Larsson, Søren Lund Kristensen, Tania Deis, Peder E. Warming, Peter L. Graversen, Morten Schou, Lars Køber, Kasper Rossing, Finn Gustafsson
Socioeconomic deprivation is associated with a lower likelihood of referral for advanced heart failure (HF) evaluation, but it is not known whether it influences rates of advanced HF therapies independently of key hemodynamic measures and comorbidity following advanced HF evaluation in a universal healthcare system. We linked data from a single-center Danish clinical registry of consecutive patients
-
-
-
-
Compartment-specific remodeling patterns in end-stage chronic obstructive pulmonary disease with and without severe pulmonary hypertension J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-19 Katarina Zeder, Leigh Matthew Marsh, Alexander Avian, Luka Brcic, Anna Birnhuber, Philipp Douschan, Vasile Foris, Teresa Sassmann, Konrad Hoetzenecker, Panja Böhm, Grazyna Kwapiszewska, Andrea Olschewski, Horst Olschewski, Gabor Kovacs
In end-stage COPD patients, severe pulmonary hypertension (PH) is frequently associated with less severe airway obstruction as compared to mild or no PH. However, the histologic correlate of this finding is not clear. To quantify remodeling of pulmonary arteries, airways and parenchyma in random samples of explanted end-stage COPD lungs. We quantified thickening of small pulmonary arteries, remodeling
-
Donor heart preservation with controlled hypothermic technology: insights into the data J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-17 Michele Gallo, Mark S. Slaughter, Jaimin R. Trivedi
-
Relationship Between Donor Derived Cell-Free DNA and Tissue-Based Rejection-Related Transcripts In Heart Transplantation J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-17 Dae Hyun Lee, Ahsan Usmani, Robby Wu, Tammi Wicks, Caroline Y Noh, Ryan Burke, Vani Ravichandran, Theresa Wolf-Doty, Ioana Dumitru, Guilherme H. Oliveira, Peter Berman, Benjamin Mackie
Endomyocardial biopsy (EMB)-based traditional microscopy remains the gold standard for the detection of cardiac allograft rejection, despite its limitation of inherent subjectivity leading to inter-reader variability. Alternative techniques now exist to surveil for allograft injury and classify rejection. Donor-derived cell-free DNA (dd-cfDNA) testing is now a validated blood-based assay used to surveil
-
Liver stiffness is associated with right heart dysfunction, cardiohepatic syndrome, and prognosis in pulmonary hypertension J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-17 Zvonimir A. Rako, Athiththan Yogeswaran, Selin Yildiz, Peter Weidemann, Daniel Zedler, Bruno Brito da Rocha, Vitalii Kryvenko, Simon Schäfer, Hossein Ardeschir Ghofrani, Werner Seeger, Nils C. Kremer, Khodr Tello
Pulmonary hypertension (PH) can lead to congestive hepatopathy, known as cardiohepatic syndrome (CHS). Hepatic congestion is associated with increased liver stiffness, which can be quantified using shear wave elastography. We aimed to investigate whether hepatic shear wave elastography detects patients at risk in the early stages of PH. Sixty-three prospectively enrolled patients undergoing right heart
-
Biting off more than you can chew: novel markers of aspiration in lung transplantation J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-16 Sandra Lindstedt, Saskia Bos, Anna Niroomand
-
Early temporary mechanical circulatory support for cardiogenic shock: real-life data from a regional cardiac assistance network J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-15 Aurore Ughetto, Jacob Eliet, Nicolas Nagot, Hélène David, Florian Bazalgette, Grégory Marin, Sébastien Kollen, Marc Mourad, Norddine Zeroual, Laurent Muller, Philippe Gaudard, Pascal Colson
Temporary mechanical circulatory support as well as multidisciplinary team approach in a regional care organization might improve survival of cardiogenic shock. No study has evaluated the relative effect of each temporary mechanical circulatory support on mortality in the context of a regional network. Prospective observational data were retrieved from patients consecutively admitted with cardiogenic
-
Macrophage and CD8 T Cell Discordance are Associated with Acute Lung Allograft Dysfunction Progression J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-15 Daniel R. Calabrese, Shivaram Yellamilli, Christina Ekstrand, Jonathan P. Singer, Steven R. Hays, Lorriana E. Leard, Rupal J. Shah, Aida Venado, Nicholas A. Kolaitis, Alyssa Perez, Alexis Combes, John R. Greenland
Acute lung allograft dysfunction (ALAD) is an imprecise syndrome denoting concern for the onset of chronic lung allograft dysfunction (CLAD). Mechanistic biomarkers are needed that stratify risk of ALAD progression to CLAD. We hypothesized that single cell investigation of bronchoalveolar lavage (BAL) cells at the time of ALAD would identify immune cells linked to progressive graft dysfunction. We
-
“Durable Left Ventricular Assist Devices as a Bridge to Transplantation in The Old and The New World” J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-14 Andrea Fernandez Valledor, Gal Rubinstein, Cathrine M. Moeller, Daniel Lorenzatti, Salwa Rahman, Changhee Lee, Daniel Oren, Marta Farrero, Gabriel T. Sayer, Nir Uriel
Heart transplantation remains the gold standard treatment for end-stage heart failure patients without contraindications. However, limited donor availability and long wait times have created a need for left ventricular assist devices (LVAD) to be used as a bridge to transplantation (BTT) in appropriately selected patients. This review provides an overview of the current state of heart transplantation
-
Extended Ischemic Time (> 15 Hours) Using Controlled Hypothermic Storage in Lung Transplantation: A Multicenter Experience J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-13 Rene Novysedlak, An-Lies Provoost, Nathaniel B. Langer, Jan Van Slambrouck, Annalisa Barbarossa, Ismail Cenik, Dirk Van Raemdonck, Robin Vos, Bart M Vanaudenaerde, Seyed Alireza Rabi, Brian C Keller, Monika Svorcova, Zuzana Ozaniak Strizova, Jiri Vachtenheim Jr, Robert Lischke, Laurens J Ceulemans
Static ice storage has long been the standard-of-care for lung preservation, although freezing injury limits ischemic time (IT). Controlled hypothermic storage (CHS) at elevated temperature could safely extend IT. This retrospective analysis assesses feasibility and safety of CHS with IT>15h. Three lung transplant (LuTx) centers (April-October 2023) included demographics, storage details, IT and short-term
-
Decoding Cardiac Reinnervation from Cardiac Autonomic Markers: A Mathematical Model Approach J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-13 Max Haberbusch, Julius Reil, Keziban Uyanik-Ünal, Christoph Schukro, Andreas Zuckermann, Francesco Moscato
Although cardiac autonomic markers are commonly used to assess cardiac reinnervation in heart transplant patients (HTx), their relationship to the degree of sympathetic and vagal cardiac reinnervation is not well understood yet. To study this relationship, we applied a mathematical model of the cardiovascular system and its autonomic control. By simulating varying levels of sympathetic and vagal efferent
-
Investigating the “sex paradox” in pulmonary arterial hypertension: results from the Pulmonary Hypertension Association Registry (PHAR) J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-13 Jacqueline T. DesJardin, Noah Kime, Nicholas A. Kolaitis, Richard A. Kronmal, Matthew R. Lammi, Stephen C. Mathai, Corey E. Ventetuolo, Teresa De Marco
Female sex is a significant risk factor for pulmonary arterial hypertension (PAH), yet males with PAH have worse survival – a phenomenon referred to as the “sex paradox” in PAH. All adult PAH patients in the Pulmonary Hypertension Association Registry (PHAR) with congruent sex and gender were included. Baseline differences in demographics, hemodynamics, functional parameters, and quality of life were
-
Impact of Anticoagulation Intensity on Blood Transfusion for Venoarterial Extracorporeal Membrane Oxygenation During Lung Transplantation J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-12 William D. Tucker, Whitney D. Gannon, Brandon Petree, John W. Stokes, Miklos D. Kertai, Caitlin T. Demarest, Eric S. Lambright, Alice Chae, Frederick W. Lombard, Jonathan D. Casey, Anil J. Trindade, Matthew Bacchetta
Venoarterial ECMO is increasingly used for mechanical circulatory support during lung transplant. Optimal intensity of intraoperative anticoagulation would be expected to mitigate thromboembolism without increasing bleeding and blood product transfusions. Yet, the optimal intensity of intraoperative anticoagulation is unknown. We performed a retrospective cohort study of 163 patients who received a
-
Access to Durable LVAD Therapy for Patients With Limited Social Support: Surveying Program-Specific Approaches J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-10 Joyce W. Wald, Mosi Bennett, Jiling Chou, Jay D. Pal, Ashwin Ravichandran, Melvin R. Echols, Kristi S. Masser, Farooq H. Sheikh, Gabriel Sayer
-
Corrigendum to “Three dimensional printed lung/thorax models - An aid to lung transplant size matching in fibrotic lung disease” J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-08 E. Khoshbin, S. Sivarajah, J. Coey, S. Clark
-
The Use of Statins in Pediatric Heart Transplantation: A Call for Standardization of Care J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-05 Elizabeth L. Profita
Abstract not available
-
Impact of minimally invasive lung transplantation on early outcomes and analgesia use: A matched cohort study J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-02 Jason Thomas, Qiudong Chen, Jad Malas, Darina Barnes, Amy Roach, Achille Peiris, Sharmini Premananthan, Aasha Krishnan, Georgina Rowe, George Gill, Lorenzo Zaffiri, Joanna Chikwe, Dominic Emerson, Pedro Catarino, Reinaldo Rampolla, Dominick Megna
Introduction Minimally invasive (MI) approaches to lung transplantation (LTx) offer the prospect of faster recovery compared to traditional incisions, however, little data exist describing the impact of surgical technique on early outcomes and analgesia use. Methods A prospectively maintained institutional registry identified 170 patients who underwent LTx between 01/2017 and 06/2022. Post-COVID acute
-
Creating superior lungs for transplantation with next-generation gene therapy during ex vivo lung perfusion J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-02 Antti I. Nykänen, Shaf Keshavjee, Mingyao Liu
Engineering donor organs to better tolerate the harmful non-immunological and immunological responses inherently related to solid organ transplantation would improve transplant outcomes. Our enhanced knowledge of ischemia-reperfusion injury, alloimmune responses and pathological fibroproliferation after organ transplantation, and the advanced toolkit available for gene therapies, have brought this
-
Circadian rhythms in solid organ transplantation J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-02-02 Brielle H. Patlin, Huram Mok, Monaj Arra, Jeffrey A. Haspel
Circadian rhythms are daily cycles in physiology that can affect medical interventions. This review considers how these rhythms may relate to solid organ transplantation. It begins by summarizing the mechanism for circadian rhythm generation known as the molecular clock, and basic research connecting the clock to biological activities germane to organ acceptance. Next follows a review of clinical evidence
-
Impact of Post-transplant Stroke and Subsequent Functional Independence on Outcomes Following Heart Transplantation Under the 2018 United States Heart Allocation System J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-19 Yeahwa Hong, Lauren V. Huckaby, Nicholas R. Hess, Luke A. Ziegler, Gavin W. Hickey, Jessica H. Huston, Michael A. Mathier, Dennis M. McNamara, Mary E. Keebler, David J. Kaczorowski
Background This study evaluates the clinical trends, risk factors, and effects of post-transplant stroke and subsequent functional independence on outcomes following orthotopic heart transplantation under the 2018 heart allocation system. Methods The UNOS registry was queried to identify adult recipients from 10/18/2018 to 12/31/2021. The cohort was stratified into two groups with and without post-transplant
-
Letter to the Editor (Commment) J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-17 Georg Hansmann, Philippe Chouvarine
Abstract not available
-
Usage of Older Donors is Associated with Higher Mortality After Heart Transplantation: A UNOS Observational Study J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-15 Abhishek Jaiswal, Michelle Kittleson, Ashwin Pillai, David Baran, William L. Baker
-
DQB1 Antigen Matching Improves Rejection-Free Survival in Pediatric Heart Transplant Recipients J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-15 Lydia K. Wright, Robert J. Gajarski, Emily Hayes, Hemant Parekh, Jessie W. Yester, Deipanjan Nandi
Introduction Presence of donor-specific antibodies (DSAs), particularly to class II antigens, remains a major challenge in pediatric heart transplantation. Donor-recipient human leukocyte antigen (HLA) matching is a potential strategy to mitigate poor outcomes associated with DSAs. We evaluated the hypothesis that antigen mismatching at the DQB1 locus is associated with worse rejection-free survival
-
Bleeding risks in preoperative plasmapheresis J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-12 Julien Fessler, Morgan Le Guen, Tiffany Pascreau
Abstract not available
-
Airway pepsinogen A4 identifies lung transplant recipients with microaspiration and predicts chronic lung allograft dysfunction J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-10 Rayoun Ramendra, Allen Duong, Chen Yang Kevin Zhang, Ella Huszti, Xuanzi Zhou, Jan Havlin, Rasheed Ghany, Marcelo Cypel, Jonathan C. Yeung, Shaf Keshavjee, Andrew T. Sage, Tereza Martinu
Background Aspiration is a known risk-factor for adverse outcomes post-lung transplantation. Airway bile acids are the gold-standard biomarker of aspiration – however they are released into the duodenum and likely reflect concurrent gastrointestinal dysmotility. Previous studies investigating total airway pepsin have found conflicting results on its relationship with adverse outcomes post-lung transplantation
-
Exploring a post-operative alternative to intra-operative therapeutic plasma exchange for sensitized lung transplant recipients J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-09 Kieran Halloran, Alim Hirji, Justin Weinkauf, Jayan Nagendran, Patricia Campbell
Abstract not available
-
Impact of center volume on outcomes after ventricular assist device implantation in pediatric patients: An analysis of the STS-Pedimacs database J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-09 Shahnawaz Amdani, Bradley S. Marino, Gerard Boyle, Amy Cassedy, Angela Lorts, David Morales, Anna Joong, Danielle Burstein, Neha Bansal, David L. Sutcliffe
Background To date, no pediatric studies have highlighted the impact of center’s ventricular assist device (VAD) volumes on post-implant outcomes. Methods Children (age <19) enrolled in Pedimacs undergoing initial left ventricular assist device implantation from 2012-2020 were included. Center volume was analyzed as a continuous and categorical variable. For categorical analysis, center volumes were
-
-
Information for Readers J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-09
Abstract not available
-
-
A Radiographic Score for Human Donor Lungs on Ex Vivo Lung Perfusion Predicts Transplant Outcomes J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-10 Bonnie T. Chao, Micheal C. McInnis, Andrew T. Sage, Jonathan C. Yeung, Marcelo Cypel, Mingyao Liu, Bo Wang, Shaf Keshavjee
Background Ex vivo lung perfusion (EVLP) is an advanced platform for isolated lung assessment and treatment. Radiographs acquired during EVLP provide a unique opportunity to assess lung injury. The purpose of our study was to define and evaluate EVLP radiographic findings and their association with lung transplant outcomes. Methods We retrospectively evaluated 113 EVLP cases from 2020-21. Radiographs
-
Does pulmonary endarterectomy improve the clinical conditions of patients with chronic thromboembolic pulmonary disease without pulmonary hypertension? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-04 Stefano Ghio, Angelo Corsico, Andrea Rapagnani, Ermelinda Borrelli, Alessia Alloni, Adele Valentini, Davide Piloni, Laura Scelsi, Catherine Klersy, Andrea Maria D’Armini
To verify whether the new hemodynamic definition of PH has any implication in treatment of CTEPD patients without PH, we retrospectively analysed the clinical and functional changes determined by pulmonary endarterectomy (PEA) in 63 CTEPD patients without PH who underwent surgery at our center, comparing those in whom the hemodynamic diagnosis of PH met recent guideline recommendations versus those
-
Acute T cell leukemia in a stable recipient of a heart transplantation J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-01-03 Yuan De Cai, Cheng-Lin Wu, Ya-Ping Chen, Yu-Ning Hu, Meng-Ta Tsai, Jun-Neng Roan
Abstract not available
-
Racial and Gender Disparities in Transplantation of Hepatitis-C+ Hearts and Lungs J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-30 Helen A. Hannan, David S. Goldberg
Background Transplanting organs from hepatitis c virus (HCV) infected donors into HCV-negative recipients has led to thousands of more transplants in the US since 2016. Studies have demonstrated disparities in utilization of kidneys from these donors due to gender and education. It is still unknown, however, if the same disparities are seen in heart and lung transplantation. Methods We used Organ Procurement
-
Recipient Outcomes with Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN Heart Registry J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-30 Roxana Moayedifar, Yasuhiro Shudo, Masashi Kawabori, Scott Silvestry, Jacob Schroder, Dan M. Meyer, Jeffrey P. Jacobs, David D’Alessandro, Andreas Zuckermann
Purpose The prevalence of end stage heart failure and patients that could benefit from heart transplantation requires an expansion of the donor pool, relying on the transplant community to continually re-evaluate and expand the use of extended criteria donor organs. Introduction of new technologies such as the Paragonix SherpaPak Cardiac Transport System aids in this shift. We seek to analyze the impact
-
Response to “Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD” by Nathan et al. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-27 R Parikh, HW Farber
Abstract not available
-
Anthropometrics are important to consider in purported sex differences in CTEPH outcomes J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-22 Katherine Bunclark, Mark Toshner
Abstract not available
-
Advanced Hemodynamic and Cluster Analysis for Identifying Novel RV function subphenotypes in Patients with Pulmonary Hypertension J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-21 Alexandra M Janowski, Keeley S Ravellette, Michael Insel, Joe G Garcia, Franz P Rischard, Rebecca R Vanderpool
Background Quantifying right ventricular (RV) function is important to describe the pathophysiology of in pulmonary hypertension (PH). Current phenotyping strategies in PH rely on few invasive hemodynamic parameters to quantify RV dysfunction severity. The aim of this study was to identify novel RV phenotypes using unsupervised clustering methods on advanced hemodynamic features of RV function. Methods
-
Chronic Lung Allograft Dysfunction is Associated with an Increased Number of Non-HLA Antibodies J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-21 Qingyong Xu, Mohamed Elrefaei, Jean-Luc Taupin, Kelley MK Hitchman, Steven Hiho, Alison Gareau, Carlo Iasella, Marilyn Marrari, Natalia Belousova, Maria Bettinotti, Tathagat Narula, Francisco Alvarez, Pablo G. Sanchez, Bronwyn Levvey, Glen Westall, Gregory Snell, Deborah J. Levine, Adriana Zeevi, Antoine Roux
Background Chronic Lung Allograft Dysfunction (CLAD) is the major cause of adverse outcomes in lung transplant recipients. Multiple factors, such as infection, alloimmunity, and autoimmunity, may lead to CLAD. Here, we aim to examine the role of non-HLA antibodies in CLAD in a large retrospective cohort. Methods We analyzed non-HLA antibodies in the pre-and post-transplant sera of 226 (100 CLAD, 126
-
Comment on the article titled “Impact of sex on outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension” published by J. Chan et al. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-21 Alejandro Cruz-Utrilla, María Jesús López-Gude, Maite Velázquez, Fernando Arribas Ynsaurriaga, Pilar Escribano-Subias
Abstract not available
-
Cardiac Magnetic Resonance Assessment of Acute Rejection and Cardiac Allograft Vasculopathy in Pediatric Heart Transplant J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-21 Sandra Kikano, Simon Lee, Debra Dodd, Justin Godown, David Bearl, Maryanne Chrisant, Kak-Chen Chan, Deipanjan Nandi, Bruce Damon, Margaret M. Samyn, Ke Yan, Kimberly Crum, Kristen George-Durrett, Lazaro Hernandez, Jonathan H. Soslow
Background In PHT, cardiac catheterization with endomyocardial biopsy (EMB) is standard practice for diagnosing AR and CAV but is costly and invasive. Objectives To evaluate the ability of cardiac magnetic resonance (CMR) to non-invasively identify differences in pediatric heart transplant (PHT) patients with acute rejection (AR) and cardiac allograft vasculopathy (CAV). Methods Patients were enrolled
-
Short-term outcomes after third-time lung transplantation: A single institution experience J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-21 Vikram F. Gupta, Samantha E. Halpern, Arya Pontula, Madison K. Krischak, John M. Reynolds, Jacob A. Klapper, Matthew G. Hartwig, John C. Haney
Background Re-operative lung transplantation (LTx) survival has improved over time such that a growing number of patients may present for third-time LTx (L3Tx). To understand the safety of L3Tx, we evaluated perioperative outcomes and three-year survival after L3Tx at a high-volume US LTx center. Methods This retrospective study included all patients who underwent bilateral L3Tx at our institution
-
Recurrent Pulmonary Hypertension After Balloon Pulmonary Angioplasty for Inoperable Chronic Thromboembolic Pulmonary Hypertension J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-19 Ryo Takano, Tatsuo Aoki, Ryotaro Asano, Jin Ueda, Akihiro Tsuji, Katsuhiro Omae, Takeshi Ogo
Background Balloon pulmonary angioplasty improves the hemodynamics of patients with inoperable chronic thromboembolic pulmonary hypertension; however, the clinical impact of recurrent pulmonary hypertension after balloon pulmonary angioplasty remains unclear. Methods We retrospectively reviewed 262 consecutive patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary
-
Informing Preconception Counseling: Outcomes Among Female Heart Transplant Recipients in the ISHLT Registry J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-13 Catriona J Bhagra, Wida S Cherikh, Heather Ross, Michelle M. Kittleson, Josef Stehlik, Alexandra Lewis, Ersilia M. DeFilippis, Francesca Macera
Introduction The numbers of women of child-bearing age undergoing heart transplantation (HT) and female pediatric HT recipients surviving to child-bearing age have increased, along with improvements in post-transplant survival. Data regarding life expectancy and comorbidities in reproductive-aged female HT recipients are needed to inform shared decision-making at the time of preconception counseling
-
-
Information for Readers J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-15
Abstract not available
-
-
Assessing and managing frailty in advanced heart failure: An International Society for Heart and Lung Transplantation consensus statement J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-15 Quin E. Denfeld, Sunita R. Jha, Erik Fung, Tiny Jaarsma, Mathew S. Maurer, Gordon R. Reeves, Jonathan Afilalo, Nadine Beerli, Lavanya Bellumkonda, Sabina De Geest, Eiran Z. Gorodeski, Emer Joyce, Jon Kobashigawa, Oliver Mauthner, Julee McDonagh, Izabella Uchmanowicz, Victoria Vaughan Dickson, JoAnn Lindenfeld, Peter Macdonald
-
Acute Right Ventricular Geometric Change Predicts Outcomes in HeartMate 3 Patients J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-07 Hideyuki Hayashi, Michael Kirschner, Alice Vinogradsky, Yuming Ning, Paul Kurlansky, Melana Yuzefpolskaya, Paolo C Colombo, Gabriel T Sayer, Nir Uriel, Yoshifumi Naka, Koji Takeda
-
Blockade of BLyS inhibits B cell responses and antibody production for the prevention of chronic transplant rejection J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-08 Tao Liao, Xiaoyi Shi, Fei Han, Yuchen Wang, Wenli Zeng, Rumin Liu, Ziyan Yan, Renfei Xia, Zhengyu Huang, Jian Xu, Yun miao
BACKGROUND Chronic rejection, closely related to the activation of B cells and donor-specific antibody (DSA) production, has unsatisfactory therapeutic outcomes. B lymphocyte stimulator (BLyS) is a major regulatory factor that controls the activation and differentiation of B cells. However, it remains unclear whether BLyS blockade can regulate B and plasma cells in the transplantation setting and affect
-
Consensus statements from the International Society for Heart and Lung Transplantation consensus conference: Heart failure–related cardiogenic shock J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-08 David A. Baran, Filio Billia, Varinder Randhawa, Jennifer A. Cowger, Christopher M. Barnett, Sharon Chih, Stephan Ensminger, Jaime Hernandez-Montfort, Shashank S. Sinha, Esther Vorovich, Alastair Proudfoot, Hoong Sern Lim, Vanessa Blumer, Douglas L. Jennings, A. Reshad Garan, Maria Florencia Renedo, Thomas C. Hanff, Manreet K. Kanwar
The last decade has brought tremendous interest in the problem of cardiogenic shock. However, the mortality rate of this syndrome approaches 50%, and other than prompt myocardial revascularization, there have been no treatments proven to improve the survival of these patients. The bulk of studies have been in patients with acute myocardial infarction, and there is little evidence to guide the clinician
-
Heart failure related cardiogenic shock: An ISHLT consensus conference content summary J. Heart Lung Transplant. (IF 6.4) Pub Date : 2023-12-08 Manreet K. Kanwar, Filio Billia, Varinder Randhawa, Jennifer A. Cowger, Christopher M. Barnett, Sharon Chih, Stephan Ensminger, Jaime Hernandez-Montfort, Shashank S. Sinha, Esther Vorovich, Alastair Proudfoot, Hoong S. Lim, Vanessa Blumer, Douglas L. Jennings, A. Reshad Garan, Maria F. Renedo, Thomas C. Hanff, David A. Baran
In recent years, there have been significant advancements in the understanding, risk-stratification, and treatment of cardiogenic shock (CS). Despite improved pharmacologic and device-based therapies for CS, short-term mortality remains as high as 50%. Most recent efforts in research have focused on CS related to acute myocardial infarction, even though heart failure related CS (HF-CS) accounts for